Remus Pharmaceuticals H1 FY27 Results and Interim Dividend Declaration
Remus Pharmaceuticals Ltd 路 Outcome 路 03 Nov 2026, 9:29 pm
Remus Pharmaceuticals H1 FY27 Results and Interim Dividend Declaration Remus Pharmaceuticals declared an interim dividend of Rs 1.00 per share (record date: 7th Nov'26) alongside its H1 FY27 results. Consolidated revenue surged 53.45% YoY to Rs 614.12 Cr, while EBITDA grew 11.22% YoY to Rs 29.93 Cr and PAT increased 14.22% YoY to Rs 24.66 Cr. Consolidated margins absorbed setup and operating costs from newly acquired subsidiaries across Bolivia, Guatemala, and Espee GCTS. Operational milestones included securing government tenders in Bolivia and Venezuela, along with approvals for Semaglutide tablets/injections and Rotigotine patches.
Original exchange filing (PDF)
More announcements from Remus Pharmaceuticals Ltd
- Remus Pharmaceuticals Limited has informed the Exchange about Transcript 路 06 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Audio Recording 路 04 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Investor Presentation 路 04 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange regarding a media release dated November 03, 2026 路 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Interim Dividend is 07-Nov-2026. 路 03 Nov 2026
- Remus Pharmaceuticals Limited has submitted to the Exchange Outcome of Board Meeting held on November 03, 2026 路 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Schedule of meet 路 29 Oct 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Dividend/Other business. 路 03 Nov 2026
